Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Caribou Biosciences (CRBU) EBIAT (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed EBIAT for 6 consecutive years, with -$26.5 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 25.36% to -$26.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$148.1 million through Dec 2025, up 0.66% year-over-year, with the annual reading at -$148.1 million for FY2025, 0.66% up from the prior year.
  • EBIAT for Q4 2025 was -$26.5 million at Caribou Biosciences, up from -$27.5 million in the prior quarter.
  • The five-year high for EBIAT was -$10.0 million in Q3 2023, with the low at -$54.1 million in Q2 2025.
  • Average EBIAT over 5 years is -$28.3 million, with a median of -$27.3 million recorded in 2022.
  • The sharpest move saw EBIAT tumbled 664.48% in 2021, then skyrocketed 62.46% in 2023.
  • Over 5 years, EBIAT stood at -$18.5 million in 2021, then plummeted by 46.05% to -$27.0 million in 2022, then fell by 27.85% to -$34.5 million in 2023, then decreased by 2.85% to -$35.5 million in 2024, then rose by 25.36% to -$26.5 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$26.5 million, -$27.5 million, and -$54.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.